Nos experts
Flavio Guzmán, M.D.
Publications de Flavio Guzmán, M.D.
Premier trimestre 2026 en revue : milsapéridone, agonistes des récepteurs GLP-1 et zuranolone
0,50 CME
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA's removal of the GLP-1 suicidality warning mean for your practice? How does ACOG's updated guidance position zuranolone for severe postpartum depression?
Guide de la venlafaxine : pharmacologie, indications, recommandations posologiques et effets indésirables
0,50 CME
This guide covers pharmacodynamics, pharmacokinetics, dosage forms, indications, side effects, and use in special populations. It also discusses venlafaxine's mechanism of action, metabolism, and FDA-approved and off-label uses.
Citalopram et escitalopram : résumé des principales différences et similitudes
0,50 CME
This article provides an in-depth comparison of citalopram and escitalopram, covering their chemical composition, pharmacokinetics, FDA-approved indications, off-label uses, potential side effects, and the risk of QT prolongation associated with both drugs. Furthermore, it addresses crucial considerations for prescribing these medications to specific patient populations.
Guide pratique de la fluoxétine : pharmacologie, indications, recommandations posologiques et effets indésirables
0,50 CME
Fluoxetine is a potent serotonin reuptake inhibitor with a long half-life. It is FDA-approved for depression, OCD, panic disorder and bulimia. Fluoxetine also has off-label uses like treating repetitive behaviors in autism. This guide covers fluoxetine's pharmacology, dosing, side effects and use in special populations.
Fluvoxamine : guide pratique — pharmacologie, indications, recommandations posologiques et effets indésirables
0,50 CME
Fluvoxamine (Luvox) is approved for OCD in both pediatric and adult patients in the U.S. There is no definitive evidence suggesting it is more effective than other SSRIs for OCD. It is also approved for depression in the UK. Fluvoxamine is an inhibitor of CYP1A2 and should not be combined with MAOIs.